CAV3 Antibody | 31-074

CAV3 Antibody | 31-074 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Dog

Homology: N/A

Immunogen: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human CAV3.

Research Area: Membrane

Tested Application: E, WB

Application: CAV3 antibody can be used for detection of CAV3 by ELISA at 1:12500. CAV3 antibody can be used for detection of CAV3 by western blot at 0.5 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50, 000 - 100, 000.

Specificiy: N/A

Positive Control 1: Cat. No. XBL-10413 - Fetal Skeletal Muscle Tissue Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 17 kDa

Validation: N/A

Isoform: N/A

Purification: Antibody is purified by peptide affinity chromatography method.

Clonality: Polyclonal

Clone: N/A

Isotype: N/A

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Concentration: batch dependent

Storage Condition: For short periods of storage (days) store at 4˚C. For longer periods of storage, store CAV3 antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles.

Alternate Name: CAV3, LQT9, VIP21, LGMD1C, VIP-21

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CAV3 is a caveolin family member, which functions as a component of the caveolae plasma membranes found in most cell types. Caveolin proteins are proposed to be scaffolding proteins for organizing and concentrating certain caveolin-interacting molecules. Mutations identified in this gene lead to interference with protein oligomerization or intra-cellular routing, disrupting caveolae formation and resulting in Limb-Girdle muscular dystrophy type-1C (LGMD-1C) , hyperCKemia or rippling muscle disease (RMD) . Alternative splicing has been identified for this locus, with inclusion or exclusion of a differentially spliced intron. In addition, transcripts utilize multiple polyA sites and contain two potential translation initiation sites.